Press Releases

 Filter by Provider

Kardigan™, a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced results from KARDINAL, a Phase 2 clinical trial evaluating the effects of tonlamarsen in patients with uncontrolled hypertension despite treatment with two or more antihypertensive medications. Data were presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.26) and simultaneously published in The Journal of the American College of Cardiology (JACC). In the clinical trial, tonlamarsen, an investigational antisense oligonucleotide (ASO) targeting angiotensinogen (AGT), demonstrated a statistically significant reduction in plasma AGT levels and a clinically meaningful reduction in in-office systolic blood pressure (oSBP) from baseline to Week 20. These results highlight the intended biological effect of tonlamarsen and support evaluation in Kardigan’s planned Phase 2b clinical trial in patients with acute severe hypertension (ASH) post-hospitalization.

Debevoise & Plimpton LLP has secured affirmance from the U.S. Court of Appeals for the Second Circuit of its 2023 summary judgment win on behalf of YPF S.A., the largest energy producer in the Republic of Argentina – defeating claims for more than $16 billion in damages and interest. This is a landmark win for YPF, affirming the dismissal of a case that has been pending in S.D.N.Y since 2015. The Second Circuit fully affirmed the District Court’s holding that YPF did not owe the alleged contractual obligations to Petersen Energía Inversora, S.A.U. and Petersen Energía, S.A.U. or Eton Park Capital Management, L.P., Eton Park Master Fund, Ltd., and Eton Park Fund, L.P., and is not liable for the damages Plaintiffs – and their litigation funder, Burford Capital – had claimed.

Plumbing emergencies rarely occur at convenient times. Burst pipes, sewage backups, and sudden flooding events can strike at any hour, leaving property owners scrambling for immediate help. Rite-A-Way Plumbing has positioned itself as a go-to emergency plumber in Boise, ID, offering 24/7 rapid response for both residential and commercial properties. With licensed professionals and specialized equipment ready to deploy at a moment's notice, the Boise-based operation continues to meet the growing demand for dependable plumbing services across the Treasure Valley.

The kitchen remains the most-used and most-renovated room in any home. In Flat Rock, MI, demand for kitchen remodeling has grown steadily as homeowners look to upgrade outdated layouts, increase storage capacity, and create spaces designed for everyday living. Uniquely Unique Building and Remodeling LLC has become a go-to resource for homeowners across the region, offering full-service kitchen renovation solutions that balance design, function, and long-term value.

With temperatures in San Antonio expected to climb past triple digits again this summer, demand for AC installation has reached new highs across the region. Texas Air Repair, a family-owned HVAC service provider based in Converse, TX, is scaling operations to meet the growing demand for reliable cooling solutions across residential and commercial properties in the San Antonio metro area. The company has been a trusted name in the local HVAC market for more than 30 years, and the upcoming season marks another chapter in meeting the region's rising cooling demands.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Yiren Digital Ltd. (“Yiren” or “the Company”) (NYSE: YRD) for violations of the securities laws.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Insulet Corporation (“Insulet” or “the Company”) (NASDAQ: PODD) for violations of the securities laws.

Fashion trends often change quickly, but certain accessories manage to remain relevant across generations. Caps are one of those items. Once considered purely casual, they have now become a key element in both streetwear and contemporary fashion.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Priority Technology Holdings, Inc. (“Priority Technology” or “the Company”) (NASDAQ: PRTH) for potential breaches of fiduciary duty on the part of its directors and management.

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT).

Takeda (TSE:4502/NYSE:TAK) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2

CAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). Litifilimab is the first humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2), which has the potential to become the first innovative therapy approved for CLE in 70 years. Part A of AMETHYST evaluated the efficacy and safety of litifilimab through week 24, with reductions in skin disease activity reported across several measures. Results are consistent with the earlier positive Phase 2 LILAC study reported in The New England Journal of Medicine. Phase 2 results from LILAC and AMETHYST supported litifilimab’s recently granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation. Results are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.

DURHAM, N.C., March 28, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics, a clinical-stage biotechnology company focused on developing targeted therapeutics in autoimmune disease, announced today the publication of results from the Phase 3 VALOR trial evaluating brepocitinib in adults with dermatomyositis (DM) in the New England Journal of Medicine (NEJM).

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented late-breaking data from its MOMENTUM trial examining the prevalence of endogenous hypercortisolism in patients with resistant hypertension at the 2026 American College of Cardiology Annual Scientific Session (ACC 2026).

New infrastructure builds on Amazon Growth Lab's work helping brands refresh 10,000+ SKUs for stronger Rufus and COSMO readiness

Injection-site “bumps” are becoming one of the most quietly discussed complications in the growing gray market peptide space — and clinicians say they’re often misunderstood until they escalate. What begins as mild swelling or irritation can develop into persistent nodules, inflammatory reactions, or even abscesses linked to sterility issues, contaminants, or inconsistent formulations. As more individuals turn to unregulated peptide sources, these outcomes are no longer isolated — they’re part of a larger pattern. California Trim Clinic is among the providers drawing attention to this shift, emphasizing that these reactions are not random side effects, but predictable consequences of products that bypass medical oversight. The clinic points to physician-guided, pharmacy-compounded peptides as the safer alternative — offering controlled sourcing, sterile preparation, and structured care that gray market channels cannot replicate.

Broomall, PA - Nailed It Roofing, a fully licensed and insured residential roofing contractor operating across New Jersey and Pennsylvania, is now actively serving homeowners in Broomall, PA. Residents of Marple Township in Delaware County can now access the company's complete range of professional roofing services, including full roof replacement, storm damage restoration, gutter installation, and hands-on insurance claim assistance.

Platform broadens coverage of free-to-play content as players increasingly seek low-risk ways to explore online casinos.

GetAFollower has delivered more than 50,000+ orders to over 51,000+ customers worldwide, reflecting the company’s steady growth and continued focus on providing reliable, high-quality social media services.

Enhanced rapid-response capabilities aim to help homeowners and businesses minimize damage and recovery time during water-related emergencies

QR Code Generator by Egoditor holds a 1.5 out of 5 TrustScore across more than 9,200 Trustpilot reviews. The complaints follow a pattern so uniform it reads less like individual grievance and more like documented business practice: user creates a QR code, prints it on physical materials, discovers days or weeks later that the code has been deactivated, and is asked to pay a recurring subscription to reactivate it. The subscription trap, a model in which a platform lets users generate and distribute QR codes during a brief free window then disables those codes once the trial lapses, has become the dominant monetization strategy across the dynamic QR code industry.

The crypto market is buzzing today as Cheems hits new milestones, and Snek records a surge in trading volumes. Amidst this excitement, one presale is capturing the attention of savvy investors: APEMARS ($APRZ) is now live, making waves in the meme coin universe. If you’re hunting for the best meme coin presales, this is the […]

AUSTIN, TX / ACCESS Newswire / March 28, 2026 / Hair loss can be unsettling long before it becomes obvious to anyone else. It often starts with small signs: a little more shedding in the shower, a thinner-looking part, a hairline that seems less full than before, or a brush that fills up faster than it used to. For many people, that is the moment when a casual interest in hair care becomes a serious search for a solution.

Lip augmentation remains one of the most requested aesthetic treatments for patients seeking fuller, more youthful, and better-defined lips. In Los Angeles, Dr. Babak Moein offers a personalized approach to lip enhancement, helping patients choose between non-surgical and surgical options based on their anatomy, goals, and desired level of correction.

Excessive underarm sweating can affect comfort, confidence, and daily life in ways that go far beyond normal perspiration. For individuals struggling with axillary hyperhidrosis, Dr. Babak Moein in Los Angeles offers an advanced treatment option using Fractora, a radiofrequency microneedling technology designed to target overactive sweat glands and provide long-lasting improvement.

Individuals struggling with stubborn pockets of fat caused by genetics, aging, or lifestyle factors now have a non-surgical option for improving body contours. VelaShape® body contouring is gaining attention in Los Angeles as a safe, FDA-approved treatment designed to reduce circumference, smooth skin, and improve the appearance of areas such as the abdomen, thighs, arms, and love handles.

Did you buy MNDY common stock between September 17, 2025, and February 6, 2026?

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Routine colon cancer screening caught the disease early, giving Billings woman more treatment options and a smoother recovery.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Did you buy ORCL common stock between June 12, 2025, and December 16, 2025?

Lindeman’s Illustrated Fairy Tale Focuses on Emotional Healing for Young Readers Southern California, USA – The children’s fantasy book The Fairy Queen and the Heart of the Lake is scheduled for publication in 2026 as an illustrated fairy tale for children and family readers.

Clearwater Cleaning is a San Diego-based cleaning company that works closely with professionals who feel daily pressure from demanding schedules and shrinking personal time. In the last quarter, the company registered a 50% increase in recurring weekly cleaning requests from residents who no longer want to spend weekends cleaning the house. The same pattern is reported by many clients. Extended working hours leave little time for cleaning. Mess builds quietly. Stress follows soon after.

NEW YORK, NY / ACCESS Newswire / March 28, 2026 / Debt consolidation is a great first step in finding debt relief. It can simplify your debt situation and potentially lower your interest rate and monthly payment.

Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?

The show also broadcasts across MENA and Latin America as sponsored programming.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting.

Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled software-as-a-medical-device (SaMD) that detects early signs of PH, a serious and progressive condition affecting the lungs and right side of the heart. The algorithm, which previously received FDA Breakthrough Device Designation, is the first PH algorithm cleared for use with standard 12-lead electrocardiograms (ECGs), making it broadly accessible across care settings.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Did you buy PYPL common stock between February 25, 2025, and February 2, 2026?

Did you buy SLNO common stock between March 26, 2025, and November 4, 2025?

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its potential as therapeutic solution for a diverse spectrum of patients with hypertriglyceridemia (HTG).

Prof. Tang brings a 10-year researched dual care system from China, combining external scalp cleaning and internal herbal balance to fight hair thinning with Tangjiahair.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Did you buy DRVN common stock between May 9, 2023, and February 24, 2026? 

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2025, both dates inclusive (the “Class Period”), have until May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio class action lawsuit. Captioned Douglas v. ImmunityBio, Inc., No. 26-cv-03261 (C.D. Cal.), the ImmunityBio class action lawsuit charges ImmunityBio and ImmunityBio’s Executive Chairman with violations of the Securities Exchange Act of 1934.